The University of Chicago Header Logo

Connection

Ravi Salgia to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about Lung Neoplasms.
Ravi Salgia
Connection Strength
28.063
Lung Neoplasms
  1. A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer. Biomolecules. 2023 10 28; 13(11).
    View in: PubMed
    Score: 0.391
  2. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816.
    View in: PubMed
    Score: 0.390
  3. Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series. Clin Lung Cancer. 2023 11; 24(7):666-671.
    View in: PubMed
    Score: 0.385
  4. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma. Cold Spring Harb Mol Case Stud. 2023 04; 9(2).
    View in: PubMed
    Score: 0.379
  5. Integration of artificial intelligence in lung cancer: Rise of the machine. Cell Rep Med. 2023 02 21; 4(2):100933.
    View in: PubMed
    Score: 0.372
  6. Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. J Clin Oncol. 2023 02 10; 41(5):1129-1131.
    View in: PubMed
    Score: 0.365
  7. Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics. Semin Cancer Biol. 2022 11; 86(Pt 2):233-246.
    View in: PubMed
    Score: 0.357
  8. The next targets for small cell lung cancer. Clin Adv Hematol Oncol. 2022 01; 20(1):35-36.
    View in: PubMed
    Score: 0.345
  9. Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. Biomolecules. 2021 12 21; 12(1).
    View in: PubMed
    Score: 0.344
  10. Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. Clin Lung Cancer. 2022 03; 23(2):e137-e139.
    View in: PubMed
    Score: 0.334
  11. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
    View in: PubMed
    Score: 0.328
  12. Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey. JCO Oncol Pract. 2021 08; 17(8):e1120-e1130.
    View in: PubMed
    Score: 0.326
  13. Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. Clin Lung Cancer. 2021 09; 22(5):e703-e707.
    View in: PubMed
    Score: 0.323
  14. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
    View in: PubMed
    Score: 0.323
  15. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Cold Spring Harb Mol Case Stud. 2020 12; 6(6).
    View in: PubMed
    Score: 0.321
  16. Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis? JCO Oncol Pract. 2021 01; 17(1):52-53.
    View in: PubMed
    Score: 0.311
  17. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncol Pract. 2021 02; 17(2):e257-e265.
    View in: PubMed
    Score: 0.311
  18. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer. 2020 08; 146:174-181.
    View in: PubMed
    Score: 0.308
  19. Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. Int J Oncol. 2020 07; 57(1):80-86.
    View in: PubMed
    Score: 0.305
  20. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magn Reson Imaging. 2020 06; 69:49-56.
    View in: PubMed
    Score: 0.304
  21. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One. 2020; 15(2):e0228188.
    View in: PubMed
    Score: 0.302
  22. The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer. Bioinformatics. 2019 08 15; 35(16):2738-2748.
    View in: PubMed
    Score: 0.292
  23. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344.
    View in: PubMed
    Score: 0.285
  24. Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treat Res. 2019; 178:3-43.
    View in: PubMed
    Score: 0.280
  25. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. J Oncol Pract. 2018 09; 14(9):569-571.
    View in: PubMed
    Score: 0.272
  26. Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract. 2018 06; 14(6):359-366.
    View in: PubMed
    Score: 0.269
  27. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327.
    View in: PubMed
    Score: 0.264
  28. EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer. 2018 Apr; 1869(2):128-137.
    View in: PubMed
    Score: 0.263
  29. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
    View in: PubMed
    Score: 0.255
  30. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
    View in: PubMed
    Score: 0.248
  31. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer. 2017 03; 105:7-13.
    View in: PubMed
    Score: 0.244
  32. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891.
    View in: PubMed
    Score: 0.240
  33. KRAS in Non-Small-Cell Lung Cancer-Reply. JAMA Oncol. 2016 10 01; 2(10):1373-1374.
    View in: PubMed
    Score: 0.240
  34. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
    View in: PubMed
    Score: 0.239
  35. MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. J Thorac Oncol. 2016 09; 11(9):1381-3.
    View in: PubMed
    Score: 0.238
  36. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. BMC Cancer. 2016 08 02; 16:568.
    View in: PubMed
    Score: 0.237
  37. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist. 2016 06; 21(6):762-70.
    View in: PubMed
    Score: 0.234
  38. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016 07; 16(7):737-49.
    View in: PubMed
    Score: 0.234
  39. Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep. 2016 Apr 15; 6:24578.
    View in: PubMed
    Score: 0.232
  40. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86.
    View in: PubMed
    Score: 0.232
  41. Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol. 2016; 12(8):1045-58.
    View in: PubMed
    Score: 0.230
  42. Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. Am J Clin Oncol. 2015 Oct; 38(5):442-7.
    View in: PubMed
    Score: 0.224
  43. Lung cancer-a fractal viewpoint. Nat Rev Clin Oncol. 2015 Nov; 12(11):664-75.
    View in: PubMed
    Score: 0.220
  44. ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. J Clin Neurosci. 2015 Dec; 22(12):1978-9.
    View in: PubMed
    Score: 0.220
  45. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641.
    View in: PubMed
    Score: 0.219
  46. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opin Drug Saf. 2015 Mar; 14(3):485-93.
    View in: PubMed
    Score: 0.214
  47. Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. Future Oncol. 2015; 11(3):489-500.
    View in: PubMed
    Score: 0.212
  48. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919.
    View in: PubMed
    Score: 0.208
  49. Mitochondrial dynamics: biology and therapy in lung cancer. Expert Opin Investig Drugs. 2014 May; 23(5):675-92.
    View in: PubMed
    Score: 0.201
  50. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117.
    View in: PubMed
    Score: 0.198
  51. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95.
    View in: PubMed
    Score: 0.197
  52. Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013 Oct; 108(5):327-33.
    View in: PubMed
    Score: 0.192
  53. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.
    View in: PubMed
    Score: 0.191
  54. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther. 2013 Jul; 14(7):679-91.
    View in: PubMed
    Score: 0.190
  55. Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases. Tumori. 2013 Mar-Apr; 99(2):e73-6.
    View in: PubMed
    Score: 0.187
  56. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1089-96.
    View in: PubMed
    Score: 0.186
  57. CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer. Am J Respir Crit Care Med. 2012 Nov 15; 186(10):940-1.
    View in: PubMed
    Score: 0.183
  58. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210.
    View in: PubMed
    Score: 0.181
  59. Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer. 2012 Sep; 51(9):841-51.
    View in: PubMed
    Score: 0.177
  60. A novel classification of lung cancer into molecular subtypes. PLoS One. 2012; 7(2):e31906.
    View in: PubMed
    Score: 0.174
  61. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 2011 Dec; 11(12):1655-62.
    View in: PubMed
    Score: 0.171
  62. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1810-1.
    View in: PubMed
    Score: 0.170
  63. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
    View in: PubMed
    Score: 0.164
  64. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther. 2011 Mar; 28(3):173-94.
    View in: PubMed
    Score: 0.162
  65. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
    View in: PubMed
    Score: 0.161
  66. Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. J Clin Pathol. 2011 Jan; 64(1):16-24.
    View in: PubMed
    Score: 0.159
  67. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem. 2010 Jun 11; 285(24):18575-85.
    View in: PubMed
    Score: 0.153
  68. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther. 2010 Mar 15; 9(6):409-16.
    View in: PubMed
    Score: 0.152
  69. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972.
    View in: PubMed
    Score: 0.151
  70. MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 2010 Jan-Mar; 4(1):146-52.
    View in: PubMed
    Score: 0.151
  71. MET receptor tyrosine kinase. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1064-5.
    View in: PubMed
    Score: 0.148
  72. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
    View in: PubMed
    Score: 0.147
  73. Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol. 2009 Apr; 36(2 Suppl 1):S52-8.
    View in: PubMed
    Score: 0.142
  74. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14.
    View in: PubMed
    Score: 0.140
  75. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol. 2009; 28(2):89-98.
    View in: PubMed
    Score: 0.140
  76. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19.
    View in: PubMed
    Score: 0.137
  77. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther. 2008 Jun; 7(6):856-63.
    View in: PubMed
    Score: 0.132
  78. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42.
    View in: PubMed
    Score: 0.131
  79. Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2007 Nov; 7(6):633-42.
    View in: PubMed
    Score: 0.129
  80. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007 Aug 06; 97(3):368-77.
    View in: PubMed
    Score: 0.127
  81. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrom Rev. 2007 May-Jun; 26(3):451-66.
    View in: PubMed
    Score: 0.125
  82. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007 Apr 15; 67(8):3529-34.
    View in: PubMed
    Score: 0.124
  83. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007 Jun; 292(6):L1488-94.
    View in: PubMed
    Score: 0.123
  84. Lung carcinoma in African Americans. Nat Clin Pract Oncol. 2007 Feb; 4(2):118-29.
    View in: PubMed
    Score: 0.123
  85. A review of topoisomerase inhibition in lung cancer. Cancer Biol Ther. 2006 Dec; 5(12):1600-7.
    View in: PubMed
    Score: 0.122
  86. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006 Nov; 11(6):687-92.
    View in: PubMed
    Score: 0.120
  87. c-Met inhibition. Clin Adv Hematol Oncol. 2006 Nov; 4(11):823-4.
    View in: PubMed
    Score: 0.120
  88. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer. 2006 Nov; 54(2):243-5.
    View in: PubMed
    Score: 0.119
  89. Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets. 2005 Jun; 9(3):533-59.
    View in: PubMed
    Score: 0.109
  90. Novel therapies in lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):343-67, vii.
    View in: PubMed
    Score: 0.108
  91. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 2005 Mar 15; 11(6):2312-9.
    View in: PubMed
    Score: 0.108
  92. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005 Feb 15; 65(4):1479-88.
    View in: PubMed
    Score: 0.107
  93. Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal. 2004 Aug 06; 4:589-604.
    View in: PubMed
    Score: 0.103
  94. Biology and novel therapeutics for neuroendocrine tumors of the lung. J Biol Regul Homeost Agents. 2004 Jul-Dec; 18(3-4):275-90.
    View in: PubMed
    Score: 0.102
  95. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004 Mar-Apr; 24(2C):1031-8.
    View in: PubMed
    Score: 0.100
  96. Novel targets for therapeutic agents in small cell lung cancer. J Natl Compr Canc Netw. 2004 Mar; 2(2):165-72.
    View in: PubMed
    Score: 0.100
  97. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer. J Environ Pathol Toxicol Oncol. 2004; 23(4):237-51.
    View in: PubMed
    Score: 0.099
  98. Small cell lung cancer: from molecular biology to novel therapeutics. J Exp Ther Oncol. 2003 Nov-Dec; 3(6):305-18.
    View in: PubMed
    Score: 0.098
  99. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81.
    View in: PubMed
    Score: 0.097
  100. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2023 11; 24(7):651-659.
    View in: PubMed
    Score: 0.097
  101. Unusual problems in breast cancer and a rare lung cancer case. Case 4. Primary lymphoepithelioma-like carcinoma of the lung. J Clin Oncol. 2003 Jun 01; 21(11):2220-2.
    View in: PubMed
    Score: 0.095
  102. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):624-30.
    View in: PubMed
    Score: 0.093
  103. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171.
    View in: PubMed
    Score: 0.093
  104. Molecular and cellular biology of small cell lung cancer. Semin Oncol. 2003 Feb; 30(1):57-71.
    View in: PubMed
    Score: 0.093
  105. Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma. Clin Lung Cancer. 2023 05; 24(3):244-251.
    View in: PubMed
    Score: 0.093
  106. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. Mol Cancer. 2023 01 04; 22(1):1.
    View in: PubMed
    Score: 0.092
  107. Molecular alterations in lung cancer. Impact on prognosis. Methods Mol Med. 2003; 75:29-38.
    View in: PubMed
    Score: 0.092
  108. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 2003; 74:113-25.
    View in: PubMed
    Score: 0.092
  109. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist. 2003; 8(1):69-75.
    View in: PubMed
    Score: 0.092
  110. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2003 Jan-Feb; 23(1A):49-62.
    View in: PubMed
    Score: 0.092
  111. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. J Environ Pathol Toxicol Oncol. 2003; 22(3):147-65.
    View in: PubMed
    Score: 0.092
  112. Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk. J Cancer Res Clin Oncol. 2023 Jul; 149(8):5231-5240.
    View in: PubMed
    Score: 0.092
  113. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002 Nov 01; 62(21):6304-11.
    View in: PubMed
    Score: 0.091
  114. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med. 2002 Oct-Dec; 6(4):539-53.
    View in: PubMed
    Score: 0.091
  115. An Updated Review on Radiation Treatment Management in Thymus Cancers. Clin Lung Cancer. 2022 Nov; 23(7):561-570.
    View in: PubMed
    Score: 0.090
  116. Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer. Radiother Oncol. 2022 08; 173:10-18.
    View in: PubMed
    Score: 0.089
  117. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002 Feb; 8(2):620-7.
    View in: PubMed
    Score: 0.087
  118. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2022 02 01; 45(2):49-54.
    View in: PubMed
    Score: 0.087
  119. Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients. J Thorac Oncol. 2022 02; 17(2):194-196.
    View in: PubMed
    Score: 0.087
  120. ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready? JCO Precis Oncol. 2021 11; 5:767-770.
    View in: PubMed
    Score: 0.085
  121. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mol Cancer Ther. 2021 10; 20(10):1820-1835.
    View in: PubMed
    Score: 0.083
  122. The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2021 08; 30(8):1498-1505.
    View in: PubMed
    Score: 0.083
  123. ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation. Mol Oncol. 2021 07; 15(7):1866-1881.
    View in: PubMed
    Score: 0.082
  124. Germline mutations and age at onset of lung adenocarcinoma. Cancer. 2021 08 01; 127(15):2801-2806.
    View in: PubMed
    Score: 0.082
  125. RNA-based therapies: A cog in the wheel of lung cancer defense. Mol Cancer. 2021 03 19; 20(1):54.
    View in: PubMed
    Score: 0.082
  126. Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Med. 2021 04; 10(8):2660-2667.
    View in: PubMed
    Score: 0.082
  127. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res. 2001 Mar-Apr; 21(2B):1241-6.
    View in: PubMed
    Score: 0.081
  128. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021 06; 16(6):1030-1041.
    View in: PubMed
    Score: 0.081
  129. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001 Feb; 10(1):77-82.
    View in: PubMed
    Score: 0.081
  130. Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Clin Lung Cancer. 2021 09; 22(5):e678-e683.
    View in: PubMed
    Score: 0.081
  131. Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Semin Cancer Biol. 2022 08; 83:57-76.
    View in: PubMed
    Score: 0.080
  132. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. Clin Lung Cancer. 2021 01; 22(1):e84-e97.
    View in: PubMed
    Score: 0.079
  133. Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. J Biol Chem. 2020 09 18; 295(38):13393-13406.
    View in: PubMed
    Score: 0.078
  134. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8.
    View in: PubMed
    Score: 0.078
  135. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022.
    View in: PubMed
    Score: 0.076
  136. Case 1: small bowel obstruction due to metastatic lung cancer. J Clin Oncol. 2000 Jan; 18(1):227-8.
    View in: PubMed
    Score: 0.075
  137. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Commun Signal. 2019 12 16; 17(1):167.
    View in: PubMed
    Score: 0.075
  138. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
    View in: PubMed
    Score: 0.073
  139. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer. 2019 07; 133:136-143.
    View in: PubMed
    Score: 0.072
  140. Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncol. 2019 Aug; 58(8):1095-1101.
    View in: PubMed
    Score: 0.071
  141. RLIP inhibition suppresses breast-to-lung metastasis. Cancer Lett. 2019 04 10; 447:24-32.
    View in: PubMed
    Score: 0.070
  142. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 07; 18(1):67-77.
    View in: PubMed
    Score: 0.070
  143. Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma. Lung Cancer. 1998 Nov; 22(2):149-52.
    View in: PubMed
    Score: 0.069
  144. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.
    View in: PubMed
    Score: 0.069
  145. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Semin Oncol. 2018 08; 45(4):210-219.
    View in: PubMed
    Score: 0.068
  146. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018 03 21; 18(1):314.
    View in: PubMed
    Score: 0.066
  147. Molecular abnormalities in lung cancer. J Clin Oncol. 1998 Mar; 16(3):1207-17.
    View in: PubMed
    Score: 0.066
  148. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185.
    View in: PubMed
    Score: 0.066
  149. Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. Eur J Oncol Nurs. 2017 Aug; 29:125-134.
    View in: PubMed
    Score: 0.063
  150. Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. Int J Cancer. 2017 08 15; 141(4):766-777.
    View in: PubMed
    Score: 0.063
  151. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev. 2017 Apr; 55:181-189.
    View in: PubMed
    Score: 0.062
  152. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Invest New Drugs. 2017 06; 35(3):334-344.
    View in: PubMed
    Score: 0.062
  153. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Sci. 2017 Mar; 108(3):488-496.
    View in: PubMed
    Score: 0.062
  154. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 2017 01 03; 10(460).
    View in: PubMed
    Score: 0.061
  155. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696.
    View in: PubMed
    Score: 0.060
  156. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
    View in: PubMed
    Score: 0.059
  157. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 2016 Mar 22; 7(12):13621-33.
    View in: PubMed
    Score: 0.058
  158. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol. 2016 Apr; 11(4):453-74.
    View in: PubMed
    Score: 0.057
  159. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. 2016 05 05; 35(18):2357-69.
    View in: PubMed
    Score: 0.055
  160. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6.
    View in: PubMed
    Score: 0.055
  161. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 2015 Aug; 26(8):1741-8.
    View in: PubMed
    Score: 0.054
  162. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2015 Jul; 89(1):43-9.
    View in: PubMed
    Score: 0.054
  163. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.
    View in: PubMed
    Score: 0.053
  164. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20; 371(21):1963-71.
    View in: PubMed
    Score: 0.052
  165. Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. J Med Screen. 2014 Dec; 21(4):207-15.
    View in: PubMed
    Score: 0.052
  166. Increased µ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014 Jul; 113 Suppl 1:i103-8.
    View in: PubMed
    Score: 0.051
  167. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577.
    View in: PubMed
    Score: 0.050
  168. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.050
  169. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. Int J Med Sci. 2013; 10(8):988-94.
    View in: PubMed
    Score: 0.048
  170. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul; 81(1):138-41.
    View in: PubMed
    Score: 0.047
  171. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
    View in: PubMed
    Score: 0.047
  172. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
    View in: PubMed
    Score: 0.046
  173. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct; 13(10):1011-9.
    View in: PubMed
    Score: 0.045
  174. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg. 2012 Jul; 144(1):25-32.
    View in: PubMed
    Score: 0.045
  175. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012 Jul; 144(1):33-8.
    View in: PubMed
    Score: 0.045
  176. The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. BMC Cancer. 2012 Jun 12; 12:235.
    View in: PubMed
    Score: 0.044
  177. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May; 7(5):856-65.
    View in: PubMed
    Score: 0.044
  178. Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012 Apr; 116(4):857-67.
    View in: PubMed
    Score: 0.044
  179. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer. 2012 Feb 28; 106(5):839-45.
    View in: PubMed
    Score: 0.043
  180. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 2012 May; 26(5):2175-86.
    View in: PubMed
    Score: 0.043
  181. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
    View in: PubMed
    Score: 0.043
  182. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70.
    View in: PubMed
    Score: 0.043
  183. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.043
  184. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5.
    View in: PubMed
    Score: 0.042
  185. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012 Jan; 39(1):27-38.
    View in: PubMed
    Score: 0.042
  186. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct; 12(11):1004-12.
    View in: PubMed
    Score: 0.042
  187. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25.
    View in: PubMed
    Score: 0.042
  188. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011 Aug 15; 17(16):5257-67.
    View in: PubMed
    Score: 0.042
  189. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50.
    View in: PubMed
    Score: 0.041
  190. An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer. 2011 Dec 01; 117(23):5344-50.
    View in: PubMed
    Score: 0.041
  191. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol. 2011 Apr; 6(4):786-9.
    View in: PubMed
    Score: 0.041
  192. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer. 2011 Sep 01; 117(17):3889-99.
    View in: PubMed
    Score: 0.041
  193. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011 Apr 01; 71(7):2423-7.
    View in: PubMed
    Score: 0.040
  194. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011 Mar; 112(3):558-67.
    View in: PubMed
    Score: 0.040
  195. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6.
    View in: PubMed
    Score: 0.040
  196. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med. 2010 Nov; 134(11):1702-5.
    View in: PubMed
    Score: 0.040
  197. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
    View in: PubMed
    Score: 0.040
  198. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010 May 20; 28(15):2598-603.
    View in: PubMed
    Score: 0.038
  199. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov; 14(11):1116-30.
    View in: PubMed
    Score: 0.037
  200. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008 Dec; 47(12):1025-37.
    View in: PubMed
    Score: 0.035
  201. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med. 2008 Dec; 132(12):1882-8.
    View in: PubMed
    Score: 0.035
  202. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene. 2009 Jan 29; 28(4):518-33.
    View in: PubMed
    Score: 0.035
  203. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.034
  204. MET as a target for treatment of chest tumors. Lung Cancer. 2009 Feb; 63(2):169-79.
    View in: PubMed
    Score: 0.034
  205. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008 Feb 20; 26(6):870-6.
    View in: PubMed
    Score: 0.033
  206. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63.
    View in: PubMed
    Score: 0.031
  207. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S52-60.
    View in: PubMed
    Score: 0.031
  208. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
    View in: PubMed
    Score: 0.031
  209. Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. Ann Thorac Surg. 2004 Aug; 78(2):450-7.
    View in: PubMed
    Score: 0.026
  210. Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res. 2004 May 01; 10(9):3020-8.
    View in: PubMed
    Score: 0.025
  211. Targeted molecules in small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):106-11.
    View in: PubMed
    Score: 0.025
  212. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003 Dec; 22(4):309-25.
    View in: PubMed
    Score: 0.025
  213. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5880-7.
    View in: PubMed
    Score: 0.025
  214. Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. Anticancer Res. 2003 Jul-Aug; 23(4):3379-96.
    View in: PubMed
    Score: 0.024
  215. Detection and analysis of lung cancer cells from body fluids using a rare event imaging system. Methods Mol Med. 2003; 75:423-30.
    View in: PubMed
    Score: 0.023
  216. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24.
    View in: PubMed
    Score: 0.022
  217. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 2022 01; 11(1):21-27.
    View in: PubMed
    Score: 0.021
  218. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol. 2001 Aug; 48(2):151-9.
    View in: PubMed
    Score: 0.021
  219. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
    View in: PubMed
    Score: 0.013
  220. AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64.
    View in: PubMed
    Score: 0.013
  221. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1104-10.
    View in: PubMed
    Score: 0.008
  222. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15; 62(18):5242-7.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.